Caroline Liu1, Maria K Mor2,3, Paul M Palevsky4,5, James S Kaufman6, Heather Thiessen Philbrook1, Steven D Weisbord4,7, Chirag R Parikh8. 1. Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Center for Health Equity Research and Promotion, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania chirag.parikh@jhmi.edu. 3. Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania. 4. Renal Section, Medical Service, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania. 5. University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 6. Division of Nephrology, Veterans Affairs New York Harbor Healthcare System and New York University School of Medicine, New York, New York. 7. Renal Section, Medical Service and Center for Health Equity Research and Promotion, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania. 8. Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, Maryland chirag.parikh@jhmi.edu.
Abstract
BACKGROUND AND OBJECTIVES: It is unknown whether iodinated contrast causes kidney parenchymal damage. Biomarkers that are more specific to nephron injury than serum creatinine may provide insight into whether contrast-associated AKI reflects tubular damage. We assessed the association between biomarker changes after contrast angiography with contrast-associated AKI and 90-day major adverse kidney events and death. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a longitudinal analysis of participants from the biomarker substudy of the Prevention of Serious Adverse Events following Angiography trial. We measured injury (kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, IL-18) and repair (monocyte chemoattractant protein-1, uromodulin, YKL-40) proteins from plasma and urine samples at baseline and 2-4 hours postangiography. We assessed the associations between absolute changes and relative ratios of biomarkers with contrast-associated AKI and 90-day major adverse kidney events and death. RESULTS: Participants (n=922) were predominately men (97%) with diabetes (82%). Mean age was 70±8 years, and eGFR was 48±13 ml/min per 1.73 m2; 73 (8%) and 60 (7%) participants experienced contrast-associated AKI and 90-day major adverse kidney events and death, respectively. No postangiography urine biomarkers were associated with contrast-associated AKI. Postangiography plasma kidney injury molecule-1 and IL-18 were significantly higher in participants with contrast-associated AKI compared with those who did not develop contrast-associated AKI: 428 (248, 745) versus 306 (179, 567) mg/dl; P=0.04 and 325 (247, 422) versus 280 (212, 366) mg/dl; P=0.009, respectively. The majority of patients did not experience an increase in urine or plasma biomarkers. Absolute changes in plasma IL-18 were comparable in participants with contrast-associated AKI (-30 [-71, -9] mg/dl) and those without contrast-associated AKI (-27 [-53, -10] mg/dl; P=0.62). Relative ratios of plasma IL-18 were also comparable in participants with contrast-associated AKI (0.91; 0.86, 0.97) and those without contrast-associated AKI (0.91; 0.85, 0.96; P=0.54). CONCLUSIONS: The lack of significant differences in the absolute changes and relative ratios of injury and repair biomarkers by contrast-associated AKI status suggests that the majority of mild contrast-associated AKI cases may be driven by hemodynamic changes at the kidney.
BACKGROUND AND OBJECTIVES: It is unknown whether iodinated contrast causes kidney parenchymal damage. Biomarkers that are more specific to nephron injury than serum creatinine may provide insight into whether contrast-associated AKI reflects tubular damage. We assessed the association between biomarker changes after contrast angiography with contrast-associated AKI and 90-day major adverse kidney events and death. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a longitudinal analysis of participants from the biomarker substudy of the Prevention of Serious Adverse Events following Angiography trial. We measured injury (kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, IL-18) and repair (monocyte chemoattractant protein-1, uromodulin, YKL-40) proteins from plasma and urine samples at baseline and 2-4 hours postangiography. We assessed the associations between absolute changes and relative ratios of biomarkers with contrast-associated AKI and 90-day major adverse kidney events and death. RESULTS: Participants (n=922) were predominately men (97%) with diabetes (82%). Mean age was 70±8 years, and eGFR was 48±13 ml/min per 1.73 m2; 73 (8%) and 60 (7%) participants experienced contrast-associated AKI and 90-day major adverse kidney events and death, respectively. No postangiography urine biomarkers were associated with contrast-associated AKI. Postangiography plasma kidney injury molecule-1 and IL-18 were significantly higher in participants with contrast-associated AKI compared with those who did not develop contrast-associated AKI: 428 (248, 745) versus 306 (179, 567) mg/dl; P=0.04 and 325 (247, 422) versus 280 (212, 366) mg/dl; P=0.009, respectively. The majority of patients did not experience an increase in urine or plasma biomarkers. Absolute changes in plasma IL-18 were comparable in participants with contrast-associated AKI (-30 [-71, -9] mg/dl) and those without contrast-associated AKI (-27 [-53, -10] mg/dl; P=0.62). Relative ratios of plasma IL-18 were also comparable in participants with contrast-associated AKI (0.91; 0.86, 0.97) and those without contrast-associated AKI (0.91; 0.85, 0.96; P=0.54). CONCLUSIONS: The lack of significant differences in the absolute changes and relative ratios of injury and repair biomarkers by contrast-associated AKI status suggests that the majority of mild contrast-associated AKI cases may be driven by hemodynamic changes at the kidney.
Authors: Insa M Schmidt; Isaac E Hall; Sujata Kale; Sik Lee; Chuan-Hua He; Yashang Lee; Geoffrey L Chupp; Gilbert W Moeckel; Chun Geun Lee; Jack A Elias; Chirag R Parikh; Lloyd G Cantley Journal: J Am Soc Nephrol Date: 2013-01-04 Impact factor: 10.121
Authors: Steven D Weisbord; Huanyu Chen; Roslyn A Stone; Kevin E Kip; Michael J Fine; Melissa I Saul; Paul M Palevsky Journal: J Am Soc Nephrol Date: 2006-08-23 Impact factor: 10.121
Authors: Katherine Xu; Paul Rosenstiel; Neal Paragas; Christian Hinze; Xiaobo Gao; Tian Huai Shen; Max Werth; Catherine Forster; Rong Deng; Efrat Bruck; Roger W Boles; Alexandra Tornato; Tejashree Gopal; Madison Jones; Justin Konig; Jacob Stauber; Vivette D'Agati; Hediye Erdjument-Bromage; Subodh Saggi; Gebhard Wagener; Kai M Schmidt-Ott; Nicholas Tatonetti; Paul Tempst; Juan A Oliver; Paolo Guarnieri; Jonathan Barasch Journal: J Am Soc Nephrol Date: 2016-12-27 Impact factor: 10.121
Authors: Tarek M El-Achkar; Ruth McCracken; Yan Liu; Monique R Heitmeier; Soline Bourgeois; Jan Ryerse; Xue-Ru Wu Journal: Am J Physiol Renal Physiol Date: 2013-02-06
Authors: Ana Karina Aranda-Rivera; Anjali Srivastava; Alfredo Cruz-Gregorio; José Pedraza-Chaverri; Shrikant R Mulay; Alexandra Scholze Journal: Antioxidants (Basel) Date: 2022-01-27
Authors: Kate Magner; Julius Vladimir Ilin; Edward G Clark; Jennifer W Y Kong; Alexandra Davis; Swapnil Hiremath Journal: JAMA Netw Open Date: 2022-07-01